Keros Therapeutics Inc (KROS) News

Form 8-K - Current report

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Keros Therapeutics Reports Recent Business Highlights and Third Quarter 2023 Financial Results

LEXINGTON, Mass., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...

Keros Therapeutics to Present at the 65th American Society of Hematology Annual Meeting and Exposition

LEXINGTON, Mass., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 8-K - Current report

Keros Therapeutics Presents Preclinical Data from its KER-065 Program at the 28th International Annual Congress of the World Muscle Society

LEXINGTON, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 8-K - Current report

Keros Therapeutics to Present at Upcoming Healthcare Conferences

LEXINGTON, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Keros Therapeutics Reports Recent Business Highlights and Second Quarter 2023 Financial Results

LEXINGTON, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros” or the “Company”...